Cullinan Therapeutics, Inc. (CGEM) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Pharmaceuticals 산업에서 운영. 본사 소재지는 Cambridge, MA, 미국. 현재 CEO는 Nadim Ahmed.
CGEM 을(를) 보유 IPO 날짜 2021-01-08, 111 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $868.55M.
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
